Ceo, Co-Founder
CurrentDeveloping radiopharmaceutical cancer therapies and scalable, chemically identical F-18 PET diagnostics with our HetSiFA platform. Our pipeline addresses several types of cancer, beginning with cancers in which gastrin-release peptide receptor (GRPR) is expressed, including metastatic prostate cancer.http://fuzionairetx.com